Johnson & Johnson is the world’s most innovative pharmaceutical company
Johnson & Johnson spent £37.1 billion on intangible assets and £11.87 billion on R&D last year
Johnson & Johnson has made it to the...
J&J to discontinue HIV vaccine trial
Johnson & Johnson said on Wednesday (January 18) that it was pulling the plug on a late-stage global trial of an HIV vaccine after the...
Valneva’s Covid-19 vaccine will compete with AstraZeneca and J&J, says GlobalData
The newly launched Covid-19 vaccine by the French pharmaceutical company Valneva will compete with AstraZeneca and Johnson & Johnson (J&J) in the European market,...
Janssen presents study to show long-term safety profile for Stelara®
The latest analysis presented by the Janssen Pharmaceutical Companies of Johnson & Johnson demonstrated long-term safety profile for ustekinumab drug, sold under the brand...